UA26846C2 - Рекомбіhаhтhий іhтерлейкіh-2 людиhи - Google Patents

Рекомбіhаhтhий іhтерлейкіh-2 людиhи

Info

Publication number
UA26846C2
UA26846C2 UA5010517A UA5010517A UA26846C2 UA 26846 C2 UA26846 C2 UA 26846C2 UA 5010517 A UA5010517 A UA 5010517A UA 5010517 A UA5010517 A UA 5010517A UA 26846 C2 UA26846 C2 UA 26846C2
Authority
UA
Ukraine
Prior art keywords
recombinant human
human interleukin
human
theirs
mitogenic
Prior art date
Application number
UA5010517A
Other languages
English (en)
Russian (ru)
Inventor
Даніель ЛАHДО
Філіпп РІБЕРОH
П'єр Ів Абекассіс
Пьер Ив Абекассис
Original Assignee
Руссель-Юклаф
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Руссель-Юклаф filed Critical Руссель-Юклаф
Publication of UA26846C2 publication Critical patent/UA26846C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Рекомбінантний інтерлейкін-2 (ІЛ-2) людини одержано із гранул продукту експресії бактеріальних клітин після трансформації їх вектором, що містить нативний ген ІЛ-2 людини шляхом солюбілізації у відновленому середовищі з хаотропним агентом та подальшим очищенням за допомогою осадження. Ця речовина володіє мітогенною, проліферативною, макрофагостимулюючою та індукуючою цитотоксичність моноядерних клітин активностями нативного ІЛ-2 людини.
UA5010517A 1988-07-28 1989-07-27 Рекомбіhаhтhий іhтерлейкіh-2 людиhи UA26846C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8810184A FR2635527B1 (fr) 1988-07-28 1988-07-28 Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament

Publications (1)

Publication Number Publication Date
UA26846C2 true UA26846C2 (uk) 1999-12-29

Family

ID=9368873

Family Applications (1)

Application Number Title Priority Date Filing Date
UA5010517A UA26846C2 (uk) 1988-07-28 1989-07-27 Рекомбіhаhтhий іhтерлейкіh-2 людиhи

Country Status (21)

Country Link
US (2) US5874076A (uk)
EP (1) EP0353150B1 (uk)
JP (1) JP3016793B2 (uk)
KR (1) KR0131070B1 (uk)
CN (1) CN1036532C (uk)
AT (1) ATE110783T1 (uk)
AU (1) AU624625B2 (uk)
DE (1) DE68917826T2 (uk)
DK (1) DK370489A (uk)
ES (1) ES2058573T3 (uk)
FI (1) FI96209C (uk)
FR (1) FR2635527B1 (uk)
HU (1) HU207099B (uk)
IE (1) IE64232B1 (uk)
IL (1) IL90975A (uk)
MX (1) MX16912A (uk)
NZ (1) NZ230111A (uk)
PT (1) PT91295B (uk)
RU (1) RU2105011C1 (uk)
UA (1) UA26846C2 (uk)
ZA (1) ZA895419B (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
FR2668368B1 (fr) * 1990-10-30 1995-03-10 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
WO1992009623A1 (fr) * 1990-11-23 1992-06-11 Roussel-Uclaf PROCEDE DE PREPARATION D'UNE PROTEINE COMPORTANT AU MOINS UN PONT DISULFURE INTRAMOLECULAIRE PAR OXYDATION, A UN pH INFERIEUR A 5,0, DE LA PROTEINE RECOMBINANTE REDUITE CORRESPONDANTE
FR2671728B1 (fr) * 1991-01-17 1995-01-20 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des pneumathorax.
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US6470207B1 (en) * 1999-03-23 2002-10-22 Surgical Navigation Technologies, Inc. Navigational guidance via computer-assisted fluoroscopic imaging
US20050203578A1 (en) * 2001-08-15 2005-09-15 Weiner Michael L. Process and apparatus for treating biological organisms
SI2251353T1 (sl) * 2003-08-07 2013-10-30 Zymogenetics, Inc. Homogeni preparati il-29
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine Inc METHODS AND COMPOSITIONS OF BIASED IL2 MUTEINS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) * 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4654830A (en) * 1984-11-27 1987-03-31 Monolithic Memories, Inc. Method and structure for disabling and replacing defective memory in a PROM
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
JPH0829113B2 (ja) * 1986-11-11 1996-03-27 武田薬品工業株式会社 ヒトインタ−ロイキン−２の製造法

Also Published As

Publication number Publication date
HU207099B (en) 1993-03-01
HUT51647A (en) 1990-05-28
IE64232B1 (en) 1995-07-26
JPH02209896A (ja) 1990-08-21
US5814314A (en) 1998-09-29
RU2105011C1 (ru) 1998-02-20
IL90975A0 (en) 1990-02-09
EP0353150A1 (fr) 1990-01-31
DK370489A (da) 1990-01-29
CN1042377A (zh) 1990-05-23
IL90975A (en) 1994-11-28
PT91295A (pt) 1990-02-08
DK370489D0 (da) 1989-07-27
EP0353150B1 (fr) 1994-08-31
FI893587A (fi) 1990-01-29
IE892443L (en) 1990-01-28
JP3016793B2 (ja) 2000-03-06
KR900001854A (ko) 1990-02-27
ZA895419B (en) 1990-09-26
KR0131070B1 (ko) 1998-04-11
ATE110783T1 (de) 1994-09-15
ES2058573T3 (es) 1994-11-01
MX16912A (es) 1993-10-01
US5874076A (en) 1999-02-23
CN1036532C (zh) 1997-11-26
FR2635527B1 (fr) 1992-06-12
FI96209B (fi) 1996-02-15
PT91295B (pt) 1995-03-01
FR2635527A1 (fr) 1990-02-23
DE68917826T2 (de) 1995-01-12
FI96209C (fi) 1996-05-27
NZ230111A (en) 1992-04-28
AU624625B2 (en) 1992-06-18
FI893587A0 (fi) 1989-07-27
AU3902489A (en) 1990-02-01
DE68917826D1 (de) 1994-10-06

Similar Documents

Publication Publication Date Title
MY110664A (en) Protein c derivatives
HK143295A (en) Fsh
AU698043B2 (en) Recombinant cells from the monocyte-macrophage cell line for gene therapy
ES8602121A1 (es) Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana
MY111402A (en) Novel uses of il-4 and/or il-10, and antibodies against the same
GR3035627T3 (en) A mammalian cytokine, il-11.
IL110284A0 (en) Viral vectors and their use in gene therapy
UA26846C2 (uk) Рекомбіhаhтhий іhтерлейкіh-2 людиhи
EP0424416A4 (en) Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
ZA200108414B (en) Akt nucleic acids, polypeptides, and uses thereof.
AU5168099A (en) Use of novel agents inducing cell death in synergy with interferons
NZ503401A (en) Use of interferon-beta (IFN-B) genes for the treatment of cancer
GR3022080T3 (en) T-cell receptor gene located within alpha locus and dna constructions
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
EP0227604A3 (en) Use of oligopeptides in the treatment of viral infections
AU3118095A (en) Dna sequences coding for the human proteins tx and ty related to the interleukin-1beta converting enzyme
AU1141695A (en) Interferon-alpha/beta binding protein, its preparation and use
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
PL313257A1 (en) Novel tripeptides useful in treating immune system and central nervous system
EP0303483A3 (en) Novel lymphokine and compositions thereof
ES8606788A1 (es) Un procedimiento para la obtencion de sobrenadantes de leu- cocitos humanos con actividades inmunomoduladoras
Mandelbaum et al. Tri-cistronic viral vectors co-expressing interleukin-12 (IL-12) and DC80 (B7-1) for the immunotherapy of cancer: studies in a myeloma model
Mao et al. Effects of murine lymphokine-activated killer (LAK) cells on proliferation of myeloid progenitor cells (CFU-GM)
WO1987003883A3 (en) Use of oligopeptides in the treatment of viral infections
BG60657B2 (en) Human recombinant interleukin-2 muteins